IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismFirst-of-its-kind meeting spotlights IMNN-001 as one
Imunon is showing new information about a medicine it's testing that might help fight ovarian cancer by using a special DNA method. When a company presents new research at an important medical meeting, it's worth watching to see if doctors and scientists think the medicine looks promising.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.